Get the Stockscreener App
16.99
1.78%
0.29
Syndax Pharmaceuticals Inc stock is traded at $16.99, with a volume of 259.79K.
It is up +1.78% in the last 24 hours and down -10.45% over the past month.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.
See More
Previous Close:
$16.70
Open:
$16.59
24h Volume:
259.79K
Relative Volume:
0.19
Market Cap:
$1.43B
Revenue:
$139.71M
Net Income/Loss:
$-209.36M
P/E Ratio:
-6.5853
EPS:
-2.58
Net Cash Flow:
$-160.60M
1W Performance:
+3.02%
1M Performance:
-10.45%
6M Performance:
-11.93%
1Y Performance:
+2.58%
1-Day Range:
$16.48
$17.01
1-Week Range:
$16.20
$17.01
52-Week Range:
$15.00
$25.34
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Name
Syndax Pharmaceuticals Inc
Sector
Industry
Phone
781-419-1400
Address
35 GATEHOUSE DRIVE, WALTHAM, MA
Compare SNDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
16.99 | 1.43B | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.83 | 119.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 82.77B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.49 | 37.02B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.37 | 32.26B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.10 | 28.24B | 3.30B | -501.07M | 1.03B | -2.1146 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-24 | Initiated | UBS | Buy |
| Jun-28-24 | Initiated | Jefferies | Buy |
| Jan-31-24 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Oct-25-23 | Initiated | BofA Securities | Buy |
| Oct-11-23 | Initiated | Goldman | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-11-23 | Initiated | Guggenheim | Buy |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jan-03-23 | Initiated | JP Morgan | Overweight |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Apr-11-22 | Initiated | H.C. Wainwright | Buy |
| Feb-15-22 | Initiated | Goldman | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-25-21 | Initiated | Citigroup | Buy |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| May-22-20 | Upgrade | Citigroup | Neutral → Buy |
| May-22-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-18-20 | Downgrade | Citigroup | Buy → Neutral |
| May-11-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-08-19 | Reiterated | H.C. Wainwright | Buy |
| Jan-04-19 | Initiated | Robert W. Baird | Outperform |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Mar-16-17 | Initiated | FBR & Co. | Outperform |
| Mar-02-17 | Initiated | Instinet | Buy |
| Oct-07-16 | Initiated | Guggenheim | Buy |
| Mar-28-16 | Initiated | Citigroup | Buy |
| Mar-28-16 | Initiated | JMP Securities | Mkt Outperform |
| Mar-28-16 | Initiated | Morgan Stanley | Overweight |
View All
Syndax Pharmaceuticals Inc Stock (SNDX) Latest News
Eventide Asset Management LLC Buys New Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals, Inc. announced that it expects to receive funding from Kyowa Hakko Kirin Co., Ltd. - Marketscreener.com
Syndax Pharmaceuticals, Inc. announced that it expects to receive $30 million in funding from Hercules Capital, Inc. - Marketscreener.com
Syndax Announces Participation at the Citi 2024 Global Healthcare Conference - StockTitan
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Purchased by Propel Bio Management LLC - MarketBeat
Syndax Pharmaceuticals' SWOT analysis: stock outlook brightens on FDA approvals - Investing.com
Long Term Trading Analysis for (SNDX) - Stock Traders Daily
Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $38.00 Price Target at JPMorgan Chase & Co. - Defense World
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Rating Lowered by StockNews.com - Defense World
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Makes New $15.17 Million Investment in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
StockNews.com Downgrades Syndax Pharmaceuticals (NASDAQ:SNDX) to Sell - MarketBeat
Atria Investments Inc Makes New Investment in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
Kura Signs Leukemia Pact with Kyowa Kirin After Losing Race to Syndax - BioSpace
Citigroup Boosts Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target to $45.00 - Defense World
What is B. Riley’s Forecast for SNDX FY2024 Earnings? - Defense World
HC Wainwright Brokers Increase Earnings Estimates for SNDX - Defense World
Jefferies Initiates Coverage of Syndax Pharmaceuticals (SNDX) with Buy Recommendation - MSN
Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Tops Revenue Estimates - MSN
FY2024 Earnings Estimate for SNDX Issued By HC Wainwright - MarketBeat
B. Riley Has Bullish Outlook for SNDX FY2024 Earnings - MarketBeat
HC Wainwright Forecasts Strong Price Appreciation for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock - Defense World
Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $45.00 - MarketBeat
First Turn Management LLC Raises Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals Leukemia Drug Wins a First-in-Class FDA Approval - MedCity News
Syndax Scores First-Mover Advantage With Approval Of Menin Inhibitor For Leukemia - Citeline
Syndax secures FDA OK for new kind of leukemia drug - BioPharma Dive
First Week of July 2025 Options Trading For Syndax Pharmaceuticals (SNDX) - Nasdaq
Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $51.00 at HC Wainwright - MarketBeat
FDA approves Syndax’s Revuforj to treat leukaemia - Pharmaceutical Technology
Syndax gets FDA okay for first-in-class leukaemia drug - pharmaphorum
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Rating Upgraded by StockNews.com - Defense World
Syndax Pharmaceuticals (NASDAQ:SNDX) Raised to Hold at StockNews.com - MarketBeat
US FDA approves Syndax's blood cancer drug - Reuters
Syndax's Revuforj Wins FDA Approval as First Menin Inhibitor for Acute Leukemia | SNDX Stock News - StockTitan
Simplify Asset Management Inc. Buys 46,992 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
(SNDX) Investment Analysis and Advice - Stock Traders Daily
Syndax Pharmaceuticals' SWOT analysis: biotech stock poised for growth amid FDA approvals - Investing.com India
Syndax Pharmaceuticals' SWOT analysis: biotech stock poised for growth amid FDA approvals By Investing.com - Investing.com South Africa
Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data - Zacks Investment Research
Syndax’s stock sinks by 25% despite AML trial meeting primary endpoint - Pharmaceutical Technology
Syndax’s revumenib meets primary results in AML trial - Yahoo Finance
Syndax shares slide despite pivotal trial success - The Pharma Letter
Syndax: Fall On NPM1m AML Data Of Revumenib Creates Buy Opportunity (NASDAQ:SNDX) - Seeking Alpha
Syndax Pharmaceuticals Inc Still Hasn’t Convinced Analysts? - Stocks Register
Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer - AOL
Syndax falls after mid-stage data for leukemia drug - MSN
Syndax stock falls after leukemia drug data (SNDX:NASDAQ) - Seeking Alpha
Syndax's Revumenib Trial Hits Key Endpoint with 47% Response Rate in AML Treatment | SNDX Stock News - StockTitan
Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $47.00 Price Target at HC Wainwright - Defense World
Creative Planning Has $318,000 Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
HC Wainwright Analysts Increase Earnings Estimates for SNDX - Defense World
Syndax Pharmaceuticals Inc Stock (SNDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.12%
0.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):